---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-262509"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T00:50:55.091836+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Syndax reports Q3 2025 revenue $45.9M, Revuforj net sales $32M; FDA approval for NPM1m AML on Oct 24

## Summary
- Total revenue $45.9M (Revuforj net $32.0M, +12% vs Q2; Niktimvo collab $13.9M).
- Net loss $60.7M ($0.70/sh) vs $84.1M ($0.98/sh) year-ago; cash $456.1M.
- Revuforj FDA-approved for R/R NPM1m AML Oct 24, 2025; added to NCCN Guidelines as cat 2A.
- Full-year 2025 R&D+SG&A guidance narrowed to $380-$385M; expects to reach profitability.
- Total Revuforj prescriptions ~850 in Q3 (+25% vs Q2); Niktimvo net sales reported by Incyte $45.8M.

## SEC filing metadata
- accession: 0001193125-25-262509
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000119312525262509/0001193125-25-262509-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000119312525262509/sndx-20251103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-262509
- JSON: https://secwatch.observer/filing/0001193125-25-262509.json
- Plain text: https://secwatch.observer/filing/0001193125-25-262509.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.